Test Price
1,500 AED✅ Home Collection Available
KRAS Codon 61 Mutation Detection Test in UAE | 1500 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary: KRAS Codon 61 Mutation Detection Test – DHA-licensed, delivers 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139). This test identifies specific DNA alterations in codon 61 of the KRAS oncogene to guide targeted therapy in colorectal, lung, and pancreatic cancers.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – tumor tissue samples (fresh in saline or FFPE block) transported under temperature-controlled conditions to our ISO-accredited laboratory.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The KRAS Codon 61 Mutation Detection Test utilizes allele-specific polymerase chain reaction (PCR) followed by Sanger sequencing confirmation to detect mutations in codon 61 of the KRAS gene. This two-step methodology ensures high specificity and eliminates false positives. The test is performed on tumor tissue samples (fresh biopsy in saline or formalin-fixed paraffin-embedded block) with a minimum of 10% tumor cellularity.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Methodology | Allele-Specific PCR + Sanger Confirmation | PCR only (no confirmatory step) |
| Diagnostic Sensitivity | 99.9% | ~95% |
| Turnaround Time | 15 Days (from sample receipt) | 20–28 Days |
| Specimen Retrieval | Secure Medical Courier (Temperature-Controlled) | Standard Postal (No Temperature Control) |
Physician Insight & Safety Protocols
“As a DHA-licensed specialist in diagnostic radiology, I emphasize that KRAS Codon 61 mutation status must always be integrated with complete clinical, radiological, and pathological findings. This highly sensitive test empowers oncologists to select optimal targeted therapy, but it never replaces a comprehensive medical evaluation. Please maintain open communication with your treating physician.” – Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA License: 61713011)
Advisory – Medication and Clinical Context
⚠️ Important Clinical Note
Do not alter or discontinue any prescribed therapy, including targeted anticancer agents, without consulting your treating oncologist. Test results require expert interpretation in conjunction with imaging and pathology reports.
Exclusion Criteria & Safety First
Contraindications for Testing
- Inadequate tumor cellularity (less than 10% tumour content) – sample will be rejected.
- Specimen not collected in appropriate medium (fresh tissue in normal saline or FFPE block).
- Unstable or critically ill patients requiring immediate emergency intervention.
- Pregnancy – genetic tests on fetal samples are not performed without explicit medical geneticist approval.
Seek Emergency Care if You Experience:
- Sudden severe abdominal pain or obstruction signs
- Acute neurological changes or seizures
- Uncontrolled bleeding or signs of severe infection
Patient FAQ & Clinical Guidance
1. What is the KRAS Codon 61 Mutation Detection test?
A: This test identifies specific DNA changes in codon 61 of the KRAS gene that influence cancer treatment choices. The results guide personalized therapy with anti-EGFR drugs in colorectal and lung cancers. It is performed on tumor tissue samples.
2. How should I prepare and provide the sample?
A: A tumor tissue sample (fresh biopsy in saline or FFPE block) with at least 10% tumor cellularity is required. The sample is collected at the hospital or clinic by the treating physician. Our medical courier then retrieves the specimen under temperature-controlled conditions and delivers it to our ISO-accredited laboratory. No home phlebotomy is available for this test.
3. Is this test covered by insurance and what support do you offer?
A: Many UAE insurers cover medically necessary KRAS testing; our team verifies coverage via WhatsApp before scheduling. We also provide a post-test teleconsultation with a DHA-licensed specialist to explain your report and answer any questions.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the oversight of the Dubai Health Authority (DHA Facility License 1143) and complies with all applicable UAE laws:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): ensuring secure handling of patient data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: governing digital health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: regulating clinical testing safety and patient consent.
All patient information is encrypted and stored in compliance with these frameworks. Your privacy and data security are our priority.
Clinical & Logistical Metadata
| Test Name | KRAS Codon 61 Mutation Detection |
| Price (AED) | 1,500 AED |
| Turnaround Time | 15 Days from sample receipt |
| Sample Type / Matrix | Tumor Tissue (Fresh in Saline or FFPE Block) |
| Methodology Used | Allele-Specific PCR + Sanger Confirmation |
| ICD-10-CM Code | C18.9 (Malignant neoplasm of colon, unspecified) – colorectal cancer context; other codes may apply based on clinical indication. |
| LOINC Code | 44635-8 (KRAS gene mutations found in tumor) |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians